Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antioxidant inflammation modulators - Reata Pharmaceuticals/AbbVie

Next Previous
Drug Profile

Research programme: antioxidant inflammation modulators - Reata Pharmaceuticals/AbbVie

Alternative Names: AIMs - Reata/Abbott; CDDO-Im; RTA 403; RTA 404; RTA dh404; RTA-411; Synthetic triterpenoids - Reata/Abbott; TBEs - Reata/Abbott; Tricyclic bis-enones - Reata/Abbott

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dartmouth College; University of Texas M. D. Anderson Cancer Center
  • Developer AbbVie; Reata Pharmaceuticals
  • Class 3-ring heterocyclic compounds; Ketones; Triterpenes
  • Mechanism of Action NF E2 related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer; Chronic obstructive pulmonary disease; Neurological disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top